In a study by Martin et al., melatonin has been found to increase DNMT activity, increase ABCG2 promoter methylation and downregulate ABCG2 expression in malignant glioma cells as well as in a subpopulation of brain cancer stem cells [191]. This evidence concerns the gene ABCG2 and brain cancer.